Islet After Kidney Transplant for Type 1 Diabetes

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Type 1 Diabetes Mellitus

In brief

The purpose of this study is to determine if prolonged administration of the anti TNF (tumor necrosis factor)-Alpha agent etanercept is associated with enhanced graft survival in patients undergoing islet after kidney transplantation.

Key facts

Study ID

NCT00784966

Run by

Virginia Commonwealth University

People needed

0

Starts

2011-08-01

Expected to finish

2017-09-01

Last updated by the study team

2014-09-16

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with type 1 diabetes mellitus, who have a stable functioning renal transplant, are taking the appropriate maintenance immunosuppression and have no severe health problems that preclude them receiving an islet transplant will be considered for inclusion.

You may not qualify if…

• Have a history of or findings suggestive of unstable diabetic complications (e.g. active eye disease)
• Active infections (clinically or by laboratory testing)
• History of current malignancy or suspicion of malignancy until properly investigated and excluded
• Liver or biliary abnormalities
• Unstable cardiovascular disease
• Findings to suggest immunological sensitization or those women who have the potential to get pregnant and are not using a sufficient method of contraception

Where it is running

• Virginia Commonwealth University Health System — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.